Literature DB >> 11770799

Association of the DD genotype and development of Japanese type 2 diabetic nephropathy.

T Gohda1, Y Makita, T Shike, M Kobayashi, K Funabiki, M Haneda, R Kikkawa, T Watanabe, T Baba, H Yoshida, Y Tomino.   

Abstract

We determined the insertion/deletion (I/D) polymorphism of the angiotensin-coverting enzyme (ACE) gene in a multicenter trial of ethnically homogeneous Japanese type 2 diabetes mellitus (DM) patients. All patients (n = 748) were divided into 5 groups as follows: group I (normoalbuminuric patients), group II (microalbuminuric patients), group III (overt albuminuric patients with serum creatinine (s-Cr) levels of less than 1.2 mg/dl), group IV (overt albuminuric patients with s-Cr levels of more than 1.3 mg/dl but excluding hemodialysis patients), and group V (hemodialysis patients). We selected patients with a diabetic duration of more than 15 years in the mild stage (groups I and II), but placed no limits on those in the advanced and end-stages (groups III, IV and V). The frequency of the DD genotype was slightly higher in the advanced and end stages. The frequency of the DD genotype in the mild stage differed from that in the end stage (II/ID/DD 47.8%/41.0%/11.2% vs. 37.0 %/43.3%/19.7% p = 0.07, II + ID/DD 88.8%/11.2% vs. 80.3%/19.7%, p < 0.05). D allele frequency in the mild stage also differed from that in the end stage (I/D 68.3%/31.7% vs. 58.7%/41.3%, p < 0.02). The presence of the DD genotype increased the risk of end-stage renal disease (ESRD) more than that of the other genotypes (odds ratio ID/II = 1.37, 95% CI 0.82-2.27; DD/II = 2.27, 95% CI 1.12-4.61). It appears that the DD genotype is associated with progression of Japanese type 2 diabetic nephropathy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11770799

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  6 in total

1.  Angiotensin-I converting enzyme insertion/deletion polymorphism and its association with diabetic nephropathy: a meta-analysis of studies reported between 1994 and 2004 and comprising 14,727 subjects.

Authors:  D P K Ng; B C Tai; D Koh; K W Tan; K S Chia
Journal:  Diabetologia       Date:  2005-04-14       Impact factor: 10.122

2.  Metabolite Regulation of Nuclear Localization of Carbohydrate-response Element-binding Protein (ChREBP): ROLE OF AMP AS AN ALLOSTERIC INHIBITOR.

Authors:  Shogo Sato; Hunmin Jung; Tsutomu Nakagawa; Robert Pawlosky; Tomomi Takeshima; Wan-Ru Lee; Haruhiko Sakiyama; Sunil Laxman; R Max Wynn; Benjamin P Tu; John B MacMillan; Jef K De Brabander; Richard L Veech; Kosaku Uyeda
Journal:  J Biol Chem       Date:  2016-03-16       Impact factor: 5.157

Review 3.  The Prevalence and Management of Diabetic Nephropathy in Asia.

Authors:  Yasuhiko Tomino; Tomohito Gohda
Journal:  Kidney Dis (Basel)       Date:  2015-04-30

Review 4.  [Therapy and prophylaxis of renal failure].

Authors:  V M Brandenburg; B Heintz; J Floege
Journal:  Internist (Berl)       Date:  2003-07       Impact factor: 0.743

5.  Polymorphism of angiotensin-converting enzyme (rs4340) and diabetic nephropathy in Caucasians with type 2 diabetes mellitus.

Authors:  M Šeruga; J Makuc; M Završnik; I Cilenšek; R Ekart; D Petrovič
Journal:  Balkan J Med Genet       Date:  2017-03-04       Impact factor: 0.519

6.  Albuminuria Increases All-Cause Mortality in Japanese Patients with Type 2 Diabetes Mellitus.

Authors:  Hitomi Miyake; Ippei Kanazawa; Toshitsugu Sugimoto
Journal:  J Clin Med       Date:  2018-08-23       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.